Search our Database of Scientific Publications and Authors

I’m looking for a

    1364 results match your criteria Clinical breast cancer[Journal]

    1 OF 28

    A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
    Clin Breast Cancer 2017 Oct 28. Epub 2017 Oct 28.
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.
    Background: Buparlisib is an oral pan-class I phosphotidyinositol-3-kinase (PI3K) inhibitor. The present phase I study evaluated the safety, pharmacokinetics, and efficacy of buparlisib with capecitabine in patients with metastatic breast cancer.

    Patients And Methods: Patients received buparlisib once daily (range, 50 to 100 mg) for 3 weeks with capecitabine twice daily (range, 1000 to 1250 mg/m(2)) for 2 weeks with a 1-week break. Read More

    Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
    Clin Breast Cancer 2017 Oct 24. Epub 2017 Oct 24.
    Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece. Electronic address:
    Background: Triple-negative breast cancer (TNBC) lacks a standard targeted therapeutic strategy and is treated with conventional cytotoxic agents. Because of the sensitivity of TNBC to platinum compounds and the synergistic effect of bevacizumab with paclitaxel we investigated the efficacy and toxicity of weekly paclitaxel and carboplatin in combination with bevacizumab as first-line treatment in metastatic TNBC.

    Patients And Methods: This phase II study followed the Simon's 2-stage optimal design. Read More

    Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History.
    Clin Breast Cancer 2017 Nov 14. Epub 2017 Nov 14.
    Department of Oncology, Haematology and Respiratory Disease, Azienda Ospedaliero-Universitaria Policlinico, University of Modena and Reggio Emilia, Modena, Italy.
    Background: We estimated the association between combined hormonal contraceptive (CHC) use and breast cancer (BC) incidence in a well-selected population of women at familial risk of BC at the Modena Family Cancer Clinic.

    Materials And Methods: We performed a retrospective cohort study by reviewing the data from 2527 women (4.5% BRCA mutation carriers, 72. Read More

    Evaluation of a New Ensemble Learning Framework for Mass Classification in Mammograms.
    Clin Breast Cancer 2017 May 22. Epub 2017 May 22.
    Department of Biomedical Engineering, Hakim Sabzevari University, Sabzevar, Iran.
    Background: Mammography is the most common screening method for diagnosis of breast cancer.

    Materials And Methods: In this study, a computer-aided system for diagnosis of benignity and malignity of the masses was implemented in mammogram images. In the computer aided diagnosis system, we first reduce the noise in the mammograms using an effective noise removal technique. Read More

    The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Clin Breast Cancer 2017 Oct 3. Epub 2017 Oct 3.
    Department of Breast Surgical Oncology, St Luke's International Hospital, Tokyo, Japan.
    Background: Although the prognostic value of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) depends on the intrinsic subtype of breast cancer, it is not clear whether chemosensitivity itself, shown by a decreasing tumor burden after NAC, contributes to improved prognosis in primary breast cancer patients, especially in patients with non-pCR. The aim of this study was to assess the prognostic effect of changes in tumor stage or nodal status after NAC in each primary breast cancer subtype.

    Patients And Methods: We assessed 719 consecutive patients with primary breast cancer who underwent surgical resection after NAC between 2001 and 2010. Read More

    Application of ACOSOG Z1071: Effect of Results on Patient Care and Surgical Decision-Making.
    Clin Breast Cancer 2017 Oct 12. Epub 2017 Oct 12.
    Division of Surgical Oncology, Levine Cancer Institute, Charlotte, NC. Electronic address:
    Background: The ACOSOG (American College of Surgeons Oncology Group) Z1071 assessed the feasibility of performing sentinel lymph node biopsy (SLNB) in node-positive patients who completed neoadjuvant chemotherapy (NACT). Historically, adoption of clinical research into practice takes years. The goal of this study was to determine the effect of Z1071 on our practice. Read More

    Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.
    Clin Breast Cancer 2017 Oct 16. Epub 2017 Oct 16.
    Department of Internal Medicine, Mayo Clinic, Rochester, MN.
    Background: Approximately half of women taking aromatase inhibitor (AI) therapy develop AI-induced arthralgia (AIA), and many might discontinue AI therapy because of the pain. Using plasma samples from the MA.27 study, we assessed several factors potentially associated with AIA. Read More

    Pleomorphic Lobular Carcinoma in Situ Diagnosed by Breast Core Biopsy: Clinicopathologic Features and Correlation With Subsequent Excision.
    Clin Breast Cancer 2017 Oct 7. Epub 2017 Oct 7.
    Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY. Electronic address:
    Introduction: Pleomorphic lobular carcinoma in situ (PLCIS) is a variant of LCIS with high-grade morphologic features. The number of case series studying PLCIS is limited, and clinical management of patients with PLCIS is controversial. We report a breast core biopsy (BCBx) series of PLCIS. Read More

    Operative and Therapeutic Advancements in Breast Cancer Metastases to the Brain.
    Clin Breast Cancer 2017 Oct 7. Epub 2017 Oct 7.
    Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA.
    Patients with breast cancer are surviving longer as the state of the art for care advances. Because patients are surviving longer with primary breast cancer, the incidence of secondary metastatic disease has risen. Metastatic breast cancer to the brain was once thought to be universally fatal. Read More

    Expanding Implementation of ACOSOG Z0011 in Surgeon Practice.
    Clin Breast Cancer 2017 Oct 13. Epub 2017 Oct 13.
    Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:
    Background: After publication of American College of Surgeons Oncology Group (ACOSOG) Z0011, surgeons at our institution limited axillary surgery to sentinel lymph node dissection (SLND) in 76% of patients meeting trial eligibility criteria. Our study objective was to assess incorporation of the trial data into practice 5 years later.

    Patients And Methods: Patients with clinical T1-2, N0 invasive breast cancer undergoing breast conserving surgery were included. Read More

    Everolimus Plus Letrozole for Treatment of Patients With HR(+), HER2(-) Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial.
    Clin Breast Cancer 2017 Sep 19. Epub 2017 Sep 19.
    Institute of Oncology, Davidoff Cancer Center, Beilinson Medical Center, Tel Aviv University, Tel Aviv, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
    Purpose: In the Breast cancer trials of OraL EveROlimus-2 (BOLERO-2) trial, everolimus plus exemestane improved progression-free survival (PFS) in patients with hormone receptor-positive (HR(+)), human epidermal growth factor receptor 2-negative (HER2(-)) advanced breast cancer (ABC) recurring or progressing on/after prior endocrine therapy (ET), suggesting that dual blockade using targeted therapy and ET was an effective treatment option. Here, we investigated the clinical benefit of combining everolimus with different endocrine partner, letrozole, in a similar patient population.

    Methods: In this phase II, open-label, single-arm, multicenter trial, postmenopausal women with HR(+), HER2(-) ABC who had recurrence/progression on/after prior ET received everolimus 10 mg daily and letrozole 2. Read More

    Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
    Clin Breast Cancer 2017 Oct 7. Epub 2017 Oct 7.
    Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
    Background: Few data exist on the influence of tumor biologic subtype on treatment response and outcomes for inflammatory breast cancer (IBC). We examined a contemporary cohort of IBC patients treated with current targeted systemic therapies, selected on the basis of tumor biologic subtype, to evaluate pathologic treatment response and cancer outcomes across biologic subtypes.

    Patients And Methods: We studied 57 clinical stage T4dM0 IBC patients operated on at our institution from October 2008 to July 2015. Read More

    Radiofrequency Ablation of Breast Cancer: A Retrospective Study.
    Clin Breast Cancer 2017 Sep 25. Epub 2017 Sep 25.
    Department of Medical Informatics, Niigata University, Chuo-ku, Niigata, Japan.
    Purpose: To validate the safety and efficacy of percutaneous radiofrequency ablation (RFA) of breast carcinomas.

    Methods: This retrospective study was conducted by the Breast Cancer Society for Minimally Invasive Therapy following approval from institutional review boards, and with the written informed consent of patients. A total of 386 patients with breast cancer treated with RFA at 10 institutions between July 2003 and June 2009 were identified and included in the analysis. Read More

    Role of BI-RADS Ultrasound Subcategories 4A to 4C in Predicting Breast Cancer.
    Clin Breast Cancer 2017 Sep 19. Epub 2017 Sep 19.
    Department of Surgery, Postgraduate Programme of Surgery, Faculty of Medicine, Rio Grande do Sul Federal University and Hospital de Clínicas de Porto Alegre University Attached Hospital, Porto Alegre, Brazil.
    Background: The Breast Imaging Reporting and Data System (BI-RADS) ultrasound (US) categorization revised in 2013 by the American College of Radiology resulted in unquestionable standardization of reports and confirmed category 3 and 5 as benign and malignant lesions, respectively. In contrast, suspected images (category 4) have subcategorization criteria, although theses have been detailed difficult to apply. The aim of the present study was to determine the role of the US 4A to 4C BI-RADS subcategories in predicting malignancy. Read More

    Evidence on Synthesized Two-dimensional Mammography Versus Digital Mammography When Using Tomosynthesis (Three-dimensional Mammography) for Population Breast Cancer Screening.
    Clin Breast Cancer 2017 Sep 28. Epub 2017 Sep 28.
    Sydney School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia. Electronic address:
    One limitation of using digital breast tomosynthesis (3-dimensional [3D] mammography) technology with conventional (2-dimensional [2D]) mammography for breast cancer (BC) screening is the increased radiation dose from dual acquisitions. To resolve this problem, synthesized 2D (s2D) reconstruction images similar to 2D mammography were developed using tomosynthesis acquisitions. The present review summarizes the evidence for s2D versus digital mammography (2D) when using tomosynthesis (3D) for BC screening to address whether using s2D instead of 2D (alongside 3D) will yield similar detection measures. Read More

    Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens.
    Clin Breast Cancer 2017 Sep 22. Epub 2017 Sep 22.
    Division of Medical Oncology, Mayo Clinic, Rochester, MN. Electronic address:
    Background: Treatment-related toxicity can vary substantially between chemotherapy regimens. In this study we evaluated the frequency of outpatient office visits among a cohort of early stage breast cancer survivors after completion of 4 different adjuvant chemotherapy regimens to better understand how differences in toxicities between regimens might affect health care use.

    Materials And Methods: We analyzed administrative claims data from a US commercial insurance database (OptumLabs) to identify women who received adjuvant doxorubicin/cyclophosphamide (AC), AC followed or preceded by docetaxel or paclitaxel (AC-T), AC concurrent with docetaxel or paclitaxel (TAC), or docetaxel/cyclophosphamide (TC) between 2008 and 2014. Read More

    Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer.
    Clin Breast Cancer 2017 Sep 27. Epub 2017 Sep 27.
    Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.
    Introduction: Contralateral prophylactic mastectomy (CPM) rates are rising, with fear implicated as a contributing factor. This study used a contralateral breast cancer (CBC) risk stratification tool to assess whether the selection of CPM is reflective of future CBC risk.

    Patients And Methods: This retrospective study evaluated 404 women with unilateral breast cancer treated with breast conservation, unilateral mastectomy, or bilateral mastectomy within a single multidisciplinary clinic. Read More

    Single Nucleotide Polymorphisms in the Acylphosphatase 2 Gene and The SNP-SNP Interactions on the Risk of Breast Cancer in Chinese Han Women.
    Clin Breast Cancer 2017 Sep 19. Epub 2017 Sep 19.
    Traditional Chinese Medicine Hospital of Wudi City, Shandong, China.
    Introduction: The purpose of this study was to investigate the impact of single nucleotide polymorphisms (SNPs) in the acylphosphatase 2 gene and the SNP-SNP interactions on breast cancer (BC) risk in Chinese Han women.

    Patients And Methods: A logistic regression model was used to examine the association between SNPs and BC risk. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. Read More

    Socioeconomic Factors, Health Behavior, and Late-Stage Diagnosis of Breast Cancer: Considering the Impact of Delay in Diagnosis.
    Clin Breast Cancer 2017 Sep 19. Epub 2017 Sep 19.
    Shiraz HIV/AIDS Research Center, Health Institute, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address:
    Background: Stage of cancer at diagnosis is one of the most important factors in patient prognosis. By controlling for diagnostic delay, this study aimed to identify factors associated with late-stage breast cancer (BC).

    Patients And Methods: From November 2014 to January 2017, required information on 497 patients who were newly diagnosed with BC was obtained from patients' medical records. Read More

    The State of Surgical Axillary Management and Adjuvant Radiotherapy for Early-stage Invasive Breast Cancer in the Modern Era.
    Clin Breast Cancer 2017 Sep 19. Epub 2017 Sep 19.
    Department of Radiation Oncology, Weill Cornell Medicine, New York, NY.
    Background: For clinical T1-2N0 breast cancer, sentinel lymph node biopsy (SLNB) has been shown in American College of Surgeons Oncology Group (ACOSOG) Z0011 to be sufficient for women with 1 to 2 positive sentinel lymph nodes with no added benefit for completion axillary lymph node dissection (ALND). Z0011 specified whole breast radiotherapy (RT) using standard tangential fields; however, later analysis showed variation in field design. We assessed nationwide practice patterns and examined factors associated with patients undergoing completion ALND and subsequent radiation field design. Read More

    The Shift From Sentinel Lymph Node Biopsy Performed Either Before or After Neoadjuvant Systemic Therapy in the Clinical Negative Nodes of Breast Cancer Patients. Results, and the Advantages and Disadvantages of Both Procedures.
    Clin Breast Cancer 2017 Sep 4. Epub 2017 Sep 4.
    Department of Gynecology.
    Background: In patients with breast cancer who are candidates for neoadjuvant therapy (NAT), the timing of when to perform sentinel lymph node biopsy (SLNB) remains under discussion. The aim of this study was to compare the advantages and disadvantages of SLNB performed before and after NAT.

    Patients And Methods: One hundred seventy-two patients, T1c to T3 and N0 (clinically and according to ultrasound) candidates for NAT were included. Read More

    Health Behavior and Quality of Life Outcome in Breast Cancer Survivors: Prevalence Rates and Predictors.
    Clin Breast Cancer 2017 Sep 18. Epub 2017 Sep 18.
    Department of Psychiatry, Psychotherapy and Psychosomatics, Division of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria.
    Purpose: Health behavior (HB) has been identified as contributing to breast cancer (BC) disease outcome. The present study was subjected to gain more in-depth insight into breast cancer survivors' (BCS) HB and its associations with patient quality of life (QOL) outcome. We investigated HB focusing on eating disturbances comparing the latter with a reference population sample (PS). Read More

    Role of (18)F-PET/CT in Predicting Prognosis of Patients With Breast Cancer After Neoadjuvant Chemotherapy.
    Clin Breast Cancer 2017 Sep 19. Epub 2017 Sep 19.
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima City, Japan. Electronic address:
    Background: Breast cancer can be assessed preoperatively and postoperatively using (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). We prospectively analyzed the maximum baseline standardized uptake value (SUVmax) derived from FDG PET/CT to predict the outcomes after neoadjuvant chemotherapy (NAC) for breast cancer.

    Patients And Methods: We assessed 130 consecutive female patients with primary breast cancer (mean age, 53. Read More

    Thirty-Year Trends of Survival and Time-Varying Effects of Prognostic Factors in Patients With Metastatic Breast Cancer-A Single Institution Experience.
    Clin Breast Cancer 2017 Sep 1. Epub 2017 Sep 1.
    Departement of Obstetrics and Gynaecology, Saint Vincent de Paul Hospital, Catholic University of Lille, Lille, France.
    Background: Metastatic breast cancer is generally considered an incurable disease. In our study we aimed to detect a time trend of survival over the past 30 years and account for time-varying effects of the prognostic factors.

    Patients And Methods: A total of 446 patients diagnosed with breast cancer at Saint Vincent de Paul Hospital, Lille, France between 1977 and 2013 who developed metastatic disease after a disease-free interval longer than 3 months and were followed-up for outcome. Read More

    Expanding the Criteria for Nipple-Sparing Mastectomy in Patients With Poor Prognostic Features.
    Clin Breast Cancer 2017 Aug 24. Epub 2017 Aug 24.
    Department of Breast Surgery, Columbia University Medical Center, New York, NY. Electronic address:
    Background: In this study we aimed to review the outcomes of nipple-sparing mastectomy (NSM) in the setting of expanded criteria: previous breast surgery/irradiation, neoadjuvant chemotherapy (NAC), post-NSM irradiation, and to assess conversion to acceptable criteria after NAC.

    Patients And Methods: In this single-institution institutional review board-approved retrospective review, we identified patients who underwent NSM after previous breast intervention or NAC from January 2010 to February 2017. Clinicopathologic features, previous breast surgeries, response rate, complications, and recurrences were recorded. Read More

    Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?
    Clin Breast Cancer 2017 Aug 24. Epub 2017 Aug 24.
    Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
    Introduction: The purpose of this study was to examine the impact of trastuzumab on acute skin and cardiac toxicity in patients with breast cancer treated with chemotherapy with or without trastuzumab and adjuvant whole breast hypofractionated radiotherapy (hypo-RT).

    Materials And Methods: The study was conducted on 727 patients treated from April 2009 to October 2016. Patients received 42. Read More

    Trends in Treatment Patterns and Clinical Outcomes in Young Women Diagnosed With Ductal Carcinoma In Situ.
    Clin Breast Cancer 2017 Aug 10. Epub 2017 Aug 10.
    Department of Epidemiology, University of California, Irvine, School of Medicine, Irvine, CA.
    Background: Although it is known that the risk of a second breast cancer event among young women diagnosed with ductal carcinoma in situ (DCIS) is higher than in older women, the effect of current treatment options on long-term outcomes in this subgroup of women remains poorly defined. We aimed to evaluate national treatment trends and determine their effect on second breast cancer risk and overall survival among young women diagnosed with DCIS.

    Materials And Methods: Surveillance, Epidemiology, and End Results data from 1998 to 2011 were used to analyze 3648 DCIS patients younger than age 40 years. Read More

    Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Clin Breast Cancer 2017 Aug 10. Epub 2017 Aug 10.
    Medical Device Consultants of Ridgewood LLC, Ridgewood, NJ. Electronic address:
    Background: Alopecia is a side effect of chemotherapy and affects a patient's quality of life. Cooling the scalp during chemotherapy might reduce alopecia. The objective of this systematic and meta-analysis was to examine the effects of scalp cooling on the end point of alopecia in randomized controlled trials. Read More

    Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
    Clin Breast Cancer 2017 Sep 1. Epub 2017 Sep 1.
    Department of Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY. Electronic address:
    Background: Poly-ADP-ribose-polymerase is an essential nuclear enzyme, involved in base-excision repair of damaged DNA. Poly-ADP-ribose-polymerase inhibition sensitizes tumor cells to cytotoxic agents, which induce DNA damage, including cyclophosphamide (C), and metronomic dosing of C may optimize potential for synergy.

    Methods: The primary objective of this phase I trial was to determine the safety and identify the recommended phase II dose of the combination of low-dose oral C (50, 75, 100, and 125 mg) once daily in combination with veliparib (V) (100, 200, and 300 mg) administered twice a day (BID) for 21-day cycles using a standard 3 + 3 design in patients with metastatic human epidermal growth factor receptor 2/neu-negative breast cancer. Read More

    Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes.
    Clin Breast Cancer 2017 Aug 19. Epub 2017 Aug 19.
    Unidad de Investigación, Fundación Hospital de Jove, Gijón, Spain; Servicio de Cirugía, Fundación Hospital de Jove, Gijón, Spain. Electronic address:
    Introduction: The objective of the present work was to evaluate the impact of the phenotype of both intratumoral mononuclear inflammatory cells (MICs) and cancer-associated fibroblast (CAFs), assessed as to their expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) on prognosis in different breast cancer subtypes.

    Materials And Methods: A total of 247 tumors of patients with primary ductal invasive breast cancer were categorized into 1 of 4 major subtypes, using the 3 standard immunohistochemical markers (estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor/Neu 2 [HER2] receptor status). An immunohistochemical study was performed using tissue arrays and specific antibodies against MMP-9, MMP-11, and MMP-14, and TIMP-1 and TIMP-2. Read More

    Assessing Changes in the Activity Levels of Breast Cancer Patients During Radiation Therapy.
    Clin Breast Cancer 2017 Aug 24. Epub 2017 Aug 24.
    Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA.
    Background: Radiation therapy (RT) is often delivered after lumpectomy for women with breast cancer. A common perceived side effect of RT is fatigue, yet its exact effect on activity levels and sleep is unknown. In this study we analyzed the change in activity levels and sleep using an activity tracking device before, during, and after RT for women with early stage breast cancer and ductal carcinoma in situ who underwent adjuvant RT. Read More

    Stromal Clusterin Expression Predicts Therapeutic Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.
    Clin Breast Cancer 2017 Aug 19. Epub 2017 Aug 19.
    Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Warren Alpert Medical School of Brown University, Providence, RI.
    Background: Expression of clusterin correlates with tumor progression and therapeutic response in several human malignancies, including breast cancer. However, its predictive value in the neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether clusterin expression in breast cancer correlated with clinical pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy (NAC). Read More

    Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
    Clin Breast Cancer 2017 Aug 18. Epub 2017 Aug 18.
    Department of Radiology and Research, Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address:
    Background: We evaluated the tumor response after neoadjuvant chemotherapy (NAC) in breast cancer patients using dynamic contrast-enhanced (DCE) magnetic resonance (MR) imaging parameters assessed using a commercially available computer-aided system. We also analyzed their correlation with pathologic tumor cellularity.

    Materials And Methods: We retrospectively reviewed the data from 130 patients with breast cancer who had undergone NAC followed by surgery from January to October 2013. Read More

    Radiomics Analysis on Ultrasound for Prediction of Biologic Behavior in Breast Invasive Ductal Carcinoma.
    Clin Breast Cancer 2017 Aug 18. Epub 2017 Aug 18.
    Department of Ultrasound, Fudan University Shanghai Cancer Center, Shanghai, China.
    Introduction: In current clinical practice, invasive ductal carcinoma is always screened using medical imaging techniques and diagnosed using immunohistochemistry. Recent studies have illustrated that radiomics approaches provide a comprehensive characterization of entire tumors and can reveal predictive or prognostic associations between the images and medical outcomes. To better reveal the underlying biology, an improved understanding between objective image features and biologic characteristics is urgently required. Read More

    Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: A Population-based Study.
    Clin Breast Cancer 2017 Aug 10. Epub 2017 Aug 10.
    Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX. Electronic address:
    Purpose: Male breast cancer (MBC) represents < 1% of breast cancer patients, and limited data exists regarding metastatic MBC. To better characterize this patient subset, we performed a population-based study examining prognostic factors among patients with stage IV MBC.

    Methods: Patients with stage IV MBC diagnosed between 1988 and 2012 were selected from the Surveillance, Epidemiology, and End Results database. Read More

    Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology.
    Clin Breast Cancer 2017 Aug 18. Epub 2017 Aug 18.
    Department of Clinical Oncology, Cairo University Hospital, Cairo, Egypt; Cairo Oncology Center (Cairocure), Cairo, Egypt. Electronic address:
    Background: Brain metastasis (BM) is a life-threatening event in breast cancer patients. Identifying patients at a high risk for BM can help to adopt screening programs and test preventive interventions. We tried to identify the incidence of BM in different stages and subtypes of breast cancer. Read More

    Reliability of Self-reported Treatment Data by Patients With Breast Cancer Compared With Medical Record Data.
    Clin Breast Cancer 2017 Aug 18. Epub 2017 Aug 18.
    Department of Medical Decision Making, Leiden University Medical Center, Leiden, The Netherlands. Electronic address:
    Objectives: Medical records are considered the gold standard for accurate treatment information. However, treatment data are increasingly obtained from questionnaires. It can be questioned whether self-reported treatment data are reliable, particularly because patients have to process a lot of information during their diagnosis and treatment process. Read More

    Improved Performance of Adjunctive Ultrasonography After Mammography Screening for Breast Cancer Among Chinese Females.
    Clin Breast Cancer 2017 Aug 15. Epub 2017 Aug 15.
    Department of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Electronic address:
    Introduction: Until now, no studies have investigated whether women other than those with dense breasts are suitable for adjunctive ultrasonography after negative mammography, and investigated whether all women with negative mammography are suitable for adjunctive ultrasonography.

    Methods: Based on the Multi-modality Independent Screening Trial in China, a total of 31,918 women aged 45 to 65 years underwent both ultrasonography and mammography. Physicians performed ultrasonography and mammography separately and were blinded to each other's findings until their interpretations had been recorded. Read More

    Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials.
    Clin Breast Cancer 2017 Jul 13. Epub 2017 Jul 13.
    Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece; Aristotle University of Thessaloniki, Thessaloniki, Greece.
    Background: The prognostic/predictive value of aberrant MYC gene copies and protein expression is not clear in breast cancer.

    Patients And Methods: Early breast cancer patients were treated with anthracycline-containing chemotherapy within 2 randomized adjuvant trials. MYC gene and centromere-8 status, as well as Myc protein expression were investigated on 1060 paraffin tumors with fluorescence in situ hybridization and immunohistochemistry, respectively. Read More

    Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
    Clin Breast Cancer 2017 Aug 9. Epub 2017 Aug 9.
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address:
    Background: Given the wide adoption of human epidermal growth factor receptor 2 (HER2)-targeted therapies for advanced HER2-positive breast cancer, we studied the natural history of patients with HER2-positive breast cancer brain metastases (BCBM) over time.

    Patients And Methods: Patients with HER2-positive BCBM identified from a prospectively maintained database at the University of North Carolina were divided into 3 cohorts by year of BCBM diagnosis. Cohorts were selected by year of HER2-targeted therapy US Food and Drug Administration approval. Read More

    Use of Breast Magnetic Resonance Imaging and Ultrasonography for Identifying Nonpalpable Axillae Metastases in Newly Diagnosed Breast Cancer Patients.
    Clin Breast Cancer 2017 Aug 9. Epub 2017 Aug 9.
    Department of Radiology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China. Electronic address:
    Background: The metastasis of axillary lymph node (ALNs) is a critical step in the initial cancer staging of newly diagnosed breast cancer (BC) patients. Various imaging modalities can enhance the sensitivity of clinical examination in assessing the ALN status.

    Patients And Methods: We enrolled 135 patients with BC, confirmed via histopathology, including 4 bilateral BC cases. Read More

    Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Clin Breast Cancer 2017 Jul 21. Epub 2017 Jul 21.
    Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan.
    Introduction: The influence of breast cancer (BC) subtype in discrepancies between pathologic complete response (pCR) and complete response by magnetic resonance imaging (MRI-CR) after neoadjuvant chemotherapy (NAC) have not been discussed well. We evaluated the association between BC subtype and pCR or only residual in situ lesion without invasive cancer (pCR/in situ(+)) in patients with MRI-CR (positive predictive value [PPV]).

    Material And Methods: From the data of 716 patients with primary BC who were diagnosed with invasive cancer and treated with NAC and then surgery from January 2009 to May 2014 at St. Read More

    RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
    Clin Breast Cancer 2017 May 22. Epub 2017 May 22.
    The West Clinic, Memphis, TN.
    Introduction: Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. In this randomized, double-blind, placebo-controlled phase III trial, we assessed first- or second-line capecitabine with sorafenib or placebo in patients with locally advanced/metastatic HER2-negative breast cancer resistant to a taxane and anthracycline and with known estrogen/progesterone receptor status.

    Patients And Methods: A total of 537 patients were randomized to capecitabine 1000 mg/m(2) orally twice per day for days 1 to 14 every 21 days with oral sorafenib 600 mg/d or placebo. Read More

    Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    Clin Breast Cancer 2017 Aug 1. Epub 2017 Aug 1.
    Department of Preventive and Restorative Dental Sciences, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.
    Introduction: Downstaging with neoadjuvant chemotherapy (NAC) might obscure indications for postmastectomy radiation (PMRT). The degree of downstaging that results in local-regional recurrence (LRR) rates low enough to omit PMRT remains controversial. We examined the rate of LRR in women who received NAC who underwent mastectomy without PMRT. Read More

    Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
    Clin Breast Cancer 2017 Jul 25. Epub 2017 Jul 25.
    Department of Integrated Traditional and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China. Electronic address:
    Background: Progression-free survival (PFS) and time to progression (TTP) have been reported to correlate with overall survival (OS) in several cancer types. To our knowledge, however, the correlation between them is unclear.

    Methods: A literature-based meta-analysis was performed to assess whether PFS and TTP can be considered reliable surrogate end points for OS in a phase 3 clinical trial of advanced breast cancer (ABC). Read More

    The Effect of Receptor Status on Mastectomy and Contralateral Prophylactic Mastectomy Rates in Early Stage Invasive Breast Carcinoma.
    Clin Breast Cancer 2017 Jun 29. Epub 2017 Jun 29.
    Division of Surgical Oncology, Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA.
    Background: There is an established relationship between hormone receptor (HR; estrogen and/or progesterone receptors) status, HER2 status, and locoregional recurrence. The purpose of this study was to analyze how HR and HER2 receptor status have influenced the surgical management trends among patients with early stage breast cancer.

    Patients And Methods: The National Cancer Database was queried for patients with cT1 to cT3, cN0, and cM0 breast carcinoma from 2004 to 2012. Read More

    Breast Lesions: Diagnosis Using Diffusion Weighted Imaging at 1.5T and 3.0T-Systematic Review and Meta-analysis.
    Clin Breast Cancer 2017 Jul 5. Epub 2017 Jul 5.
    Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address:
    Introduction: We compared the diagnostic performance of diffusion weighted imaging (DWI) acquired with 1.5T and 3.0T magnetic resonance (MR) units in differentiating malignant breast lesions from benign ones. Read More

    1 OF 28